ReviewMolecular biology reports2026
Tetramethylpyrazine modulates the Nrf2/JNK axis to intervene in ferroptosis and neuroinflammation after spinal cord injury: an integrated perspective from antioxidant to regenerative therapy.
Review in Molecular biology reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The interplay between ferroptosis and neuroinflammation during secondary injury after spinal cord injury (SCI) critically drives permanent neurological dysfunction. Targeting both processes simultaneously is a promising therapeutic strategy. Tetramethylpyrazine (TMP), the main active component of Ligusticum chuanxiong, exhibits multi-target neuroprotective properties. This review systematically summarizes TMP's role in inhibiting ferroptosis and neuroinflammation after SCI by modulating the Nrf2/JNK signaling axis. We first outline TMP's chemical structure, bioavailability, and protective effects in SCI models. Next, we elucidate the Nrf2/ARE pathway as a hub for anti-ferroptosis defense and the JNK/AP-1 pathway as a driver of inflammation and apoptosis. We then explore crosstalk between these pathways via ROS, Trx-1, and p62. Existing evidence positions TMP as a "pathway crosstalk" modulator that activates Nrf2 and inhibits JNK through multiple mechanisms, including Keap1/ASK1 modification, ROS scavenging, and adaptor protein regulation. From a spatiotemporal perspective, we analyze the phased evolution of ferroptosis and inflammation, proposing TMP's time-sequential dual regulation: early-phase anti-ferroptosis and late-phase anti-inflammation. Finally, we identify current research limitations in mechanistic depth, pathway crosstalk evidence, and translational studies, and offer future directions. This review provides an integrated viewpoint for TMP in SCI treatment, a paradigm for understanding multi-target natural products, and a theoretical foundation for shifting from antioxidant to pro-regenerative strategies.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.